<DOC>
	<DOCNO>NCT01983475</DOCNO>
	<brief_summary>Sublesional bone loss acute spinal cord injury ( SCI ) sudden , progressive , dramatic . After depletion bone mass loss architectural integrity , may difficult , even possible , restore skeletal mass strength . Denosumab relative new , highly potent anti-resorptive agent proven efficacy postmenopausal osteoporosis improve bone mass solid tumor patient prevent skeletal-related event great extent bisphosphonate administration . In person complete motor lesion , bisphosphonates effective reduce bone loss knee , site great relevance increase risk fracture . Anti-RANKL therapy appear potent bisphosphonates animal model bone loss due immobilization , suggest treatment denosumab may prove efficacious therapy person acute SCI preserve bone mass strength .</brief_summary>
	<brief_title>Denosumab Administration After Spinal Cord Injury</brief_title>
	<detailed_description>The primary objective study test efficacy potent anti-resorptive agent , denosumab [ receptor activator nuclear factor-κB ligand ( RANKL ) antibody ; Amgen Inc. ] preserve bone mass hip knee trabecular connectivity knee acute SCI . Setting : patient enrollment , study drug administration DXA scan complete Kessler Institute Rehabilitation ( KIR ) pQCT measurement perform Columbia University . A Randomized , double-blind , placebo-controlled parallel group trial . Twenty-four subject acute , motor complete SCI ( ≤12 week ) admit Kessler Institute Rehabilitation ( KIR ) recruit participation . The age study participation male age 18 65 year old female age 18 50 year old . Primary outcome measure BMD measure DXA microarchitecture measure pQCT hip knee .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>1 . Complete motor SCI [ American Spinal Injury Association Impairment Scale ( AIS ) grade A B ] ; 2 . Duration injury &lt; 12 week ; 3 . Males age 18 65 year old female age 18 50 year old . 1 . Extensive lifethreatening injury addition SCI ; 2 . Acute fracture extensive bone trauma ; 3 . History prior bone disease ( Paget 's hyperparathyroidism , osteoporosis , etc . ) 4 . Post menopausal woman ; 5 . Men know hypogonadism prior SCI ; 6 . Anabolic Steroid hormonal therapy ; within past year longer six month ; 7 . Hyperthyroidism ; 8 . Cushing 's disease syndrome ; 9 . Severe underlie chronic disease ; 10 . Heterotopic ossification knee region ( HO limit hip region exclude subject participation ) ; 11 . History chronic alcohol abuse ; 12 . Diagnosis Hypocalcemia ; 13 . Pregnancy ; 14 . Existing dental condition/dental infection 15 . Any patient taking bisphosphonate heterotopic ossification ( HO ) ; 16 . Current diagnosis cancer history cancer ; 17 . Any patient receiving moderate high dose corticosteroid ( &gt; 40 mg/d prednisone equivalent dose corticosteroid ) long one week , include drug administer attempt preserve neurological function time acute SCI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Dual Energy X-ray Absorptiometry</keyword>
</DOC>